三阴性乳腺癌分子靶向治疗的研究进展

Research development of triple negative breast cancer targeted therapy

三阴性乳腺癌(TNBC)是雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)均阴性的乳腺癌,具有独特的病理和分子生物学特性,表现为复发早、进展快、生存期短和预后较其他类型乳腺癌差的特点。除手术治疗外,化疗是其主要的全身治疗手段。目前靶向治疗正逐步应用于乳腺癌的临床治疗中,对TNBC靶向治疗的深入研究,将有助于临床采取有效的治疗方法以提高其疗效。

Triple negative breast cancer （TNBC） is a subgroup of breast cancers, defined by a lack of the expressions of estrogen, progesterone and HER2 receptors, with its exclusive pathological and molecular biological characteristics. TNBC is associated with increased risk for distant metastases, early recurrence, short lifetime and poorer prognosis than other type of breast cancer. Besides operation, chemotherapy is the major therapy for TNBC. Currently the targeted therapy is applied to clinical therapy gradually, and it might benefit the patients with TNBC. A deeper insight into the targeted therapy of TNBC may lead to improved therapies and better clinical outcomes of the disease.